CLINICAL TRIALS PROFILE FOR LUMAKRAS
✉ Email this page to a colleague
All Clinical Trials for LUMAKRAS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05054725 ↗ | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Recruiting | Amgen | Phase 2 | 2021-10-01 | The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC |
| NCT05054725 ↗ | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Recruiting | Sanofi | Phase 2 | 2021-10-01 | The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC |
| NCT05054725 ↗ | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Recruiting | Revolution Medicines, Inc. | Phase 2 | 2021-10-01 | The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC |
| NCT05251038 ↗ | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | Not yet recruiting | Amgen | Phase 1/Phase 2 | 2022-05-01 | This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy. |
| NCT05251038 ↗ | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | Not yet recruiting | Devalingam Mahalingam | Phase 1/Phase 2 | 2022-05-01 | This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy. |
| NCT05374538 ↗ | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | Not yet recruiting | Westat | Phase 1 | 2022-06-01 | This is a Phase 1 study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer(NSCLC). |
| NCT05374538 ↗ | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | Not yet recruiting | Vitrac Therapeutics, LLC | Phase 1 | 2022-06-01 | This is a Phase 1 study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer(NSCLC). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LUMAKRAS
Condition Name
Clinical Trial Locations for LUMAKRAS
Trials by Country
Clinical Trial Progress for LUMAKRAS
Clinical Trial Phase
Clinical Trial Sponsors for LUMAKRAS
Sponsor Name
